The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Sale of assets | - | - | 0 | 0 |
| Net cash provided by(used in) investing activities | - | - | 0 | 0 |
| Reverse stock split rounding adjustment | - | - | 0 | - |
| Loss on sale of assets | - | - | 0 | 0 |
| Amortization of discount on preferred stock | - | - | 0 | 0 |
| Other liabilities-Nonrelated Party | - | - | - | -212,316 |
| Inventory | - | - | 0 | 0 |
| Amortization on intangible assets | - | - | 284,759 | 554,913 |
| Other liabilities-Related Party | - | - | - | 9,175 |
| Accrued liabilities - related parties | - | - | -30,000 | 30,000 |
| Prepaid expenses | - | - | 100,000 | 0 |
| Net loss | -3,403,141 | -2,769,370 | -7,618,776 | -10,255,309 |
| Depreciation | 250 | 255 | 255 | 502 |
| Issuance of common stock for services | 589,107 | 60,000 | 5,543,101 | 5,113,591 |
| Loss from settlement | - | -125,624 | - | - |
| Loss from debt extinguishment related parties | - | 106,237 | -125,625 | - |
| Options vested for stock-based compensation | 1,090,114 | -33,471 | 1,099,793 | 101,958 |
| Amortization of intagible assets | 276,815 | 1,122,639 | - | - |
| Due from related party-Related Party | - | 20,056 | - | - |
| Amortization of license agreement | 14,523 | 164,927 | -260,186 | 695,811 |
| Impairment of license agreement-Related Party | - | -1,239,942 | - | - |
| Operating lease right of use asset | 13,800 | 20,257 | 16,459 | 31,823 |
| Prepaid expenses-Related Party | -120 | 120 | - | - |
| Prepaid expenses-Nonrelated Party | -6,124 | 7,021 | - | - |
| Deposits | 16,942 | -16,957 | - | - |
| Accounts payable and accrued liabilities | 113,118 | -98,169 | -276,656 | 430,494 |
| Operating lease right of use liabilities | -13,800 | -21,251 | -17,950 | -34,845 |
| Payroll tax liabilities | -6,124 | 4,961 | 1,487 | 2,973 |
| Other liabilities | -9,191 | -4,042 | -212,316 | - |
| Net cash used in operating activities | -1,311,343 | -1,077,761 | -1,241,264 | -3,531,230 |
| Proceeds from borrowings on notes payable | - | 0 | 0 | 500,000 |
| Proceeds from borrowings on notes payable - related parties | - | 75,000 | 0 | 100,000 |
| Proceeds from sales of common stock | - | 2,214,999 | 1,324,571 | 1,085,785 |
| Proceeds from sales of series b convertible preferred stock | - | 0 | 0 | 100,000 |
| Proceeds from exercise of warrants | - | 0 | 297,000 | 630,000 |
| Collection of subscriptions receivable | - | 0 | 1,150,000 | - |
| Proceeds from exercise of warrants | - | - | - | 1,150,000 |
| Repayment of borrowings on notes payable - related parties | - | 206,500 | - | - |
| Net cash provided by financing activities | - | 2,083,499 | 1,621,571 | 3,565,785 |
| End of period | -1,311,343 | 1,005,738 | 380,307 | 34,555 |
| Beginning of period | 1,486,338 | -422,628 | -42,366 | 58,653 |
| Effects of currency translation on cash and cash equivalents | -433 | -681 | -45 | 7,811 |
| End of period | 174,562 | 1,005,057 | 380,262 | 101,019 |
MANGOCEUTICALS, INC. (MGRX)
MANGOCEUTICALS, INC. (MGRX)